⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25376956 | 0.97 | CXCR3 (0.37) | — | |
| SCHEMBL30562884 | 0.97 | — | — | |
| SCHEMBL25375805 | 0.97 | CXCR3 (0.37) | — | |
| SCHEMBL25374676 | 0.97 | CXCR3 (0.37) | — | |
| SCHEMBL13858930 | 0.97 | — | — | |
| SCHEMBL4872937 | 0.90 | — | — | |
| Methacrylic Acid SCHEMBL3910125 | 0.77 | HDAC4 (0.35) | — | |
| SCHEMBL7218513 | 0.75 | — | — | |
| SCHEMBL25365091 | 0.67 | — | — | |
| SCHEMBL14201919 | 0.67 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 53 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3632910-B1 | 3,4-DIHYDROQUINOLINONES AS FXR RECEPTOR AGONISTS | CSPC ZHONGQI PHARMACEUTICAL TECH SHIJIAZHUANG CO LTD (CN) | 2024-07-17 | — | — | EP | disclosed |
| EP-4393916-A1 | NITROGEN-CONTAINING HETEROCYCLIC DERIVATIVE INHIBITOR, AND PREPARATION METHOD THEREFOR AND USE THEREOF | Shanghai Hansoh Biomedical Co., Ltd. (CN) | 2024-07-03 | — | — | EP | disclosed |
| EP-4289823-A1 | SUBSTITUTED PYRIDAZINE PHENOL DERIVATIVES | Medshine Discovery Inc. (CN) | 2023-12-13 | — | — | EP | disclosed |
| WO-2023162998-A1 | COMPOSITION INCLUDING IODO COMPOUND AND USE FOR SAME | 東ソー株式会社 | 2023-08-31 | — | — | WO | disclosed |
| WO-2023096304-A1 | ISOXAZOLE DERIVATIVE OR PHARMACEUTICALLY ACCEPTABLE SALT THEREOF AND USE THEREOF | 한양대학교 에리카산학협력단 | 2023-06-01 | — | — | WO | disclosed |
| US-20230079107-A1 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF HUMAN IMMUNODEFICIENCY VIRUS | CIDARA THERAPEUTICS, INC. | 2023-03-16 | — | — | US | disclosed |
| WO-2023280177-A1 | SMALL MOLECULE COMPOUND TARGETING BCL9/β-CATENIN INTERACTION | 南通聚太生物科技有限公司 | 2023-01-12 | — | — | WO | disclosed |
| EP-2892646-B1 | HYDROCONVERSION MULTI-METALLIC CATALYST | CHEVRON USA INC (US) | 2021-10-20 | — | — | EP | disclosed |
| WO-2021203025-A1 | 1 H-PYRAZOLO[4,3-G]ISOQUINOLINE AND 1 H-PYRAZOLO[4,3-G]QUINOLINE DERIVATIVES AS ALPHA-1 -ANTITRYPSIN MODULATORS FOR TREATING ALPHA-1 -ANTITRYPSIN DEFICIENCY (AATD) | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2021-10-07 | — | — | WO | disclosed |
| EP-3194443-B1 | TARGETING CYTOTOXIC CELLS WITH CHIMERIC RECEPTORS FOR ADOPTIVE IMMUNOTHERAPY | NOVARTIS AG (CH) | 2021-07-14 | — | — | EP | disclosed |
| EP-2343299-A1 | Heteroaryl substituted pyrrolo[2,3-b]pyridines and pyrrolo[2,3-b]pyrimidines as Janus kinase inhibitors | Incyte Corporation (US) | 2011-07-13 | — | — | EP | disclosed |
| EP-2343298-A1 | Heteroaryl substituted pyrrolo[2,3-b]pyridines and pyrrolo[2,3-b]pyrimidines as Janus kinase inhibitors | Incyte Corporation (US) | 2011-07-13 | — | — | EP | disclosed |
| US-20090030036-A1 | Nuclear receptor binding agents | GTX, INC. | 2009-01-29 | — | — | US | disclosed |
| EP-0628030-B1 | 2,3,4,5-TETRAHYDRO-1H --3-BENZAZEPINES HAVING ANTI-PSYCHOTIC ACTIVITY, AND SYNTHESIS OF $g(a)-SUBSTITUTED-ARYLACETAMIDES | SCHERING CORP (US) | 2002-12-11 | — | — | EP | disclosed |
| US-5530125-A | REACTING ARYLACETAMIDE WITH STRONG BASE IN INERT APROTIC SOLVENT, THEN WITH SPECIFIED REACTANT IN PRESENCE OF TRANSITION METAL CATALYST TO ADD ALPHA-SUBSTITUENT,REDUCING TO AMINE | SCHERING CORPORTION (US) | 1996-06-25 | — | — | US | disclosed |
| EP-0628030-A1 | 2,3,4,5-TETRAHYDRO-1H --3-BENZAZEPINES HAVING ANTI-PSYCHOTIC ACTIVITY, AND SYNTHESIS OF $g(a)-SUBSTITUTED-ARYLACETAMIDES | SCHERING CORPORATION (US) | 1994-12-14 | — | — | EP | disclosed |
| WO-1993016997-A1 | 2,3,4,5-TETRAHYDRO-1H^_-3-BENZAZEPINES HAVING ANTI-PSYCHOTIC ACTIVITY, AND SYNTHESIS OF α-SUBSTITUTED-ARYLACETAMIDES | SCHERING CORPORATION (US) | 1993-09-02 | — | — | WO | disclosed |
| US-5241065-A | Selectively antagonize dopamine D-1 receptors | SCHERING CORPORATION (US) | 1993-08-31 | — | — | US | disclosed |
| US-4061635-A | ANALGESIC, NEUROLEPTIC | WARNER-LAMBERT COMPANY (US) | 1977-12-06 | — | — | US | disclosed |
| US-3957851-A | 1-PHENYL-4-AMINO-CYCLOHEX-2-ENE-1-CARBOXYLIC ACID ETHYL ESTERS | WARNER-LAMBERT COMPANY (US) | 1976-05-18 | — | — | US | disclosed |